MX388717B - Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. - Google Patents

Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.

Info

Publication number
MX388717B
MX388717B MX2018015120A MX2018015120A MX388717B MX 388717 B MX388717 B MX 388717B MX 2018015120 A MX2018015120 A MX 2018015120A MX 2018015120 A MX2018015120 A MX 2018015120A MX 388717 B MX388717 B MX 388717B
Authority
MX
Mexico
Prior art keywords
difluoroacetamide
dioxopiperidin
oxoisoindolin
chlorophenyl
methyl
Prior art date
Application number
MX2018015120A
Other languages
English (en)
Spanish (es)
Other versions
MX2018015120A (es
Inventor
Antonia Lopez-Girona
Gang Lu
Irit Rappley
Kyle Macbeth
Michael Pourdehnad
Paul Hollenbach
Soraya Carrancio
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2018015120A publication Critical patent/MX2018015120A/es
Publication of MX388717B publication Critical patent/MX388717B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018015120A 2016-06-06 2017-06-05 Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. MX388717B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346344P 2016-06-06 2016-06-06
PCT/US2017/035892 WO2017214014A1 (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Publications (2)

Publication Number Publication Date
MX2018015120A MX2018015120A (es) 2019-04-15
MX388717B true MX388717B (es) 2025-03-20

Family

ID=60482040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015120A MX388717B (es) 2016-06-06 2017-06-05 Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.

Country Status (15)

Country Link
US (4) US10245258B2 (https=)
EP (1) EP3463358A4 (https=)
JP (1) JP7163281B2 (https=)
KR (1) KR20190015300A (https=)
CN (2) CN109414436A (https=)
AU (2) AU2017278114B2 (https=)
BR (1) BR112018075206A2 (https=)
CA (1) CA3026396A1 (https=)
CL (1) CL2018003499A1 (https=)
EA (1) EA201892746A1 (https=)
IL (1) IL262565B (https=)
MX (1) MX388717B (https=)
SG (1) SG11201809501PA (https=)
WO (1) WO2017214014A1 (https=)
ZA (1) ZA201807105B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CA3010801A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US11535603B1 (en) 2016-09-30 2022-12-27 Deuterx, Llc Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
KR20210110616A (ko) * 2018-12-31 2021-09-08 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-5-일)메틸)-2,2-다이플루오로아세트아마이드의 조성물 및 사용 방법
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
WO2021080955A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
JP2022554346A (ja) * 2019-11-05 2022-12-28 セルジーン コーポレーション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
AU2020396543A1 (en) 2019-12-06 2022-06-16 Celgene Corporation Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EP4121051A4 (en) * 2020-03-16 2024-04-17 Celgene Corporation COMBINATION THERAPY FOR ACUTE MYELOID LEUKEMIA
AR123492A1 (es) * 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
KR20240066906A (ko) * 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20090175869A1 (en) * 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
KR101845320B1 (ko) 2009-05-20 2018-04-04 하이브리제닉스 에스에이 이네칼시톨의 신규한 치료 용도
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
PT3077004T (pt) * 2013-12-05 2020-04-16 Hoffmann La Roche Novo tratamento de combinação para a leucemia mieloide aguda (lma)
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3399981B1 (en) 2016-01-08 2023-08-02 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
WO2017120437A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CN108430473B (zh) 2016-01-08 2021-08-31 细胞基因公司 抗增殖化合物以及其药物组合物和用途

Also Published As

Publication number Publication date
IL262565B (en) 2022-08-01
CL2018003499A1 (es) 2019-03-15
US20210154182A1 (en) 2021-05-27
ZA201807105B (en) 2020-01-29
US20230158009A1 (en) 2023-05-25
IL262565A (en) 2018-12-31
JP2019517587A (ja) 2019-06-24
EA201892746A1 (ru) 2019-06-28
JP7163281B2 (ja) 2022-10-31
US20190175573A1 (en) 2019-06-13
WO2017214014A1 (en) 2017-12-14
AU2017278114B2 (en) 2023-01-12
AU2017278114A1 (en) 2018-11-29
CA3026396A1 (en) 2017-12-14
US20170348298A1 (en) 2017-12-07
US10245258B2 (en) 2019-04-02
EP3463358A1 (en) 2019-04-10
AU2023202159A1 (en) 2023-05-04
CN115282149A (zh) 2022-11-04
MX2018015120A (es) 2019-04-15
EP3463358A4 (en) 2020-07-22
US11590117B2 (en) 2023-02-28
CN109414436A (zh) 2019-03-01
BR112018075206A2 (pt) 2019-03-19
KR20190015300A (ko) 2019-02-13
SG11201809501PA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
MX388717B (es) Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
ZA202202097B (en) Amino pyrimidine ssao inhibitors
MX2022001410A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA033689B9 (ru) Ингибиторы g12c kras
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MX2017000366A (es) Terapia de combinacion para el cancer.
MX2022011523A (es) Terapia combinada para leucemia mielógena aguda.
NZ738229A (en) Delivery systems for controlled drug release
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
MX376029B (es) Compuestos de isoindol.
MX2022005371A (es) Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2018006779A (es) Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
MX2023013011A (es) Métodos de tratamiento con n-((r)-1-(3-cloropiridin-2-il)- 2,2,2-trifluoroetil)-2-((s)-2,6-dioxopiperidin-3-il)-1- oxoisoindolin-5-carboxamida.
EA202090176A1 (ru) Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов